XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT

XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT

XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT

XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Adicet Bio Inc

Error: Cannot read properties of null (reading '1')

Announcement: ACET 10-K Annual Report

Analyst Summary:
Adicet Bio, a clinical stage biotechnology company pioneering gamma delta T cell therapies for cancer, reported its financial results for Q4 and the year ended December 31, 2022. The company demonstrated strong execution in advancing its gamma delta T cell therapy pipeline and clinical proof of concept. Chen Schor, President and CEO, highlighted that the company is enrolling patients for its ongoing trial for relapsed or refractory B-cell NHL, with efficacy, durability, and safety data expected to be reported in Q2 2023. Additionally, Adicet expects to submit an IND for ADI-925, its novel CAd gamma delta T cell product candidate in H2 2023. Adicet also presented preclinical data for its four new pipeline programs at SITC Annual Meeting last November, providing additional detail on its emerging pipeline of allogeneic CAR and CAd gamma delta T cell therapy product candidates. The company’s cash and cash equivalents securities as of December 31, 2022, are expected to be sufficient to fund its operating expenses into H1 2025. 

Management Commentary:
“The strategic focus of our pipeline event has delivered positive momentum for the Adicet business, with significant achievements across our pipeline programs in 2022, including our ADI-001 program, ADI-925 IND preparation, and the appointment of Dr. Nancy Boman, a veteran biotech and pharmaceutical executive, to our team," said Chen Schor, President and CEO of Adicet Bio. 

Forward-Looking Statements:
This release contains forward-looking statements relating to the business and operations of Adicet Bio that are subject to risks and uncertainties that may cause actual results to differ. These forward-looking statements include Adicet Bio’s expected cash runway, the success and timing of its ongoing and planned clinical trials, and regulatory approvals of its product candidates. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, among others, those detailed in Adicet's Annual Report on Form 10-K filed with the SEC.

$ACET reports strong pipeline progress and financial results for Q4 2022

Announcement: ACET 8-K Special Filing

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Announcement: ACET 10-K Annual Report

Announcement: ACET 10-K Annual Report

$ACET reports strong pipeline progress and financial results for Q4 2022

$ACET reports strong pipeline progress and financial results for Q4 2022

Announcement: ACET 8-K Special Filing

Announcement: ACET 8-K Special Filing

Announcement: ACET SC 13G/A Statement of acquisition of beneficial ownership by individuals - amendment

Announcement: ACET SC 13G/A Statement of acquisition of beneficial ownership by individuals - amendment

Announcement: ACET SC 13G/A Statement of acquisition of beneficial ownership by individuals - amendment

Announcement: ACET SC 13G/A Statement of acquisition of beneficial ownership by individuals - amendment

Announcement: ACET SC 13G/A Statement of acquisition of beneficial ownership by individuals - amendment

Announcement: ACET SC 13G/A Statement of acquisition of beneficial ownership by individuals - amendment